Multimodality treatment of pancreatic cancer with liver metastases using chemotherapy, radiation therapy, and/or Chinese herbal medicine

Pancreas

Volumn 40, Issue 1, 2011, Pages 120-125

  Ouyang, Huaqiang ^a,b   Wang, Peng ^a,b   Meng, Zhiqiang ^a,b   Chen, Zhen ^a,b   Yu, Er'Xin ^a,b   Jin, Huan ^a   Chang, David Z ^c   Liao, Zhongxing ^c   Cohen, Lorenzo ^c   Liu, Luming ^a,b  

^a FUDAN UNIVERSITY   (China)

^b Cancer Hospital ^*  (Australia)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

liver metastases; multimodality treatment; pancreatic cancer; prognosis

Indexed keywords

CA 19-9 ANTIGEN; HERBACEOUS AGENT;

ADULT; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHINESE HERB; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DRUGS, CHINESE HERBAL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 78650959439     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181e6e398     Document Type: Article

References (37)

1. Hawes RH, Xiong Q,Waxman I, et al. A multispeciality approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol. 2000;95:17-31.
2. Meenk HG, Incrocci L, Kazemier G, et al. Adjuvant 5-FU based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. Dig Surg. 2005;22:321-328.
3. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001;94:153-156.
4. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies. Ann Surg. 2006;144:10-15.
5. Winter JM, Cameron JL, Campbell KA, et al. 1423 Pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg. 2006;10:1199-1210; discussion 1210-1211.
6. Pawlik TM, Abdalla EK, Barnett CC, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg. 2005;140:584-589; discussion 589-591.
7. Schnall SF, Macdonald JS. Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol. 1996;23:220-228.
8. Gleisner AL, Assumpcao L, Cameron JL, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110:2484-2492.
9. Müller MW, Friess H, Köninger J, et al. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg. 2008;195:221-228.
10. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin. 2008;58:71-96.
11. Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg. 1994; 81:882-885.
12. Glimelius B, Hoffmann K, Sjoden P-O, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593-600.
13. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002;94:902-910.
14. Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:8033-8040. (Pubitemid 46657405)
15. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of Cancer and Leukemia Group B. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol. 2007;25:18S. Abstract 4508.
16. Gemcitabine plus bevacizumab no better than gemcitabine alone in clinical study of 600 patients with pancreatic cancer. Cancer Biol Ther. 2007;6:137.
17. Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110:1227-1234.
18. Berkson BM, Rubin DM, Berkson AJ. The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol. Integr Cancer Ther. 2006;5:83-89.
19. Guillem P, Mornex F, Partensky C. Prolonged survival after resection of pancreatic cancer with a solitary hepatic metastasis. Hepatogastroenterology. 2004;51:603-605.
20. SuzukiY, Ku Y, Tominaga M, et al. Two-staged treatment with local resection and percutaneous isolated hepatic chemoperfusion for advanced pancreatic cancer with multiple liver metastases: report of a case. Hepatogastroenterology. 2001;48:574-577.
21. Ikeda M, Okada S, Tokuuye K, et al. Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer. 2001;91:490-495. (Pubitemid 32105694)
22. Yang GY, Wagner TD, Fuss M, et al. Multimodality approaches for pancreatic cancer. CA Cancer J Clin. 2005;55:352-367.
23. Calvet X, Bruit J, Ginès P, et al. Prognostic factors of hepatocellular carcinoma in the west: a multivariate analysis of 206 patients. Hepatology. 1990;12:753-760.
24. Furuse J, Maru Y, Yoshino M, et al. Hepatic arterial infusion of 5-fluorouracil for liver metastases from pancreatic carcinoma: results from a pilot study. Hepatogastroenterology. 2001;48:208-211.
25. Ishii H, Furuse J, Nagase M, et al. Hepatic arterial infusion of 5-fluorouracil and extrabeam radiotherapy for liver metastases from pancreatic carcinoma. Hepatogastroenterology. 2004;51:1175-1178.
26. Dragovich T, Burris H, Loehrer P, et al. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Oncol. 2008;31:157-162.
27. Morizane C, Okusaka T, Furuse J, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009;63:313-319.
28. Fujino Y, Ueda T, Kamigaki T, et al. Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer. Pancreas. 2007;34:335-339.
29. Krishnan S, Rana V, Janjan NA, et al. Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. Cancer. 2006;107:2589-2596.
30. Park JK, Yoon YB, Kim YT, et al. Survival and prognostic factors of unresectable pancreatic cancer. J Clin Gastroenterol. 2008;42:86-91.
31. Tanaka T, Ikeda M, Okusaka T, et al. Prognostic factors in Japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol. 2008;38(11): 755-761.
32. Maréchal R, Demols A, Gay F, et al. Prognostic factors and prognostic index for chemonaBve and gemcitabine-refractory patients with advanced pancreatic cancer. Oncology. 2007;73(1-2):41-51.
33. Buchler MW, Kleeff J, Friess H. Surgical treatment of pancreatic cancer. J Am Coll Surg. 2007;205:S81YS86.
34. Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2007;14:118-127.
35. Hazard L, Tward JD, Szabo A, et al. Radiation therapy is associated with improved survival in patients with pancreatic adenocarcinoma: results of a study from the Surveillance, Epidemiology, and End Results (SEER) registry data. Cancer. 2007;110:2191-2201.
36. Wu F, Wang ZB, Zhu H, et al. Feasibility of US-guided high-intensity focused ultrasound treatment in patients with advanced pancreatic cancer: initial experience. Radiology. 2005;236:1034-1040.
37. Fu J, Liu LM, Shen J, et al. Effects of QYHJ decoction on expression of MDR in transplantation tumors of pancreatic cancer in nude mice. Chin J Basic Med Tradit Chin Med. 2007;13:289-291.